Signaling Pathways in Pheochromocytomas and Paragangliomas: Prospects for Future Therapies

Familial pheochromocytoma

(2014) Zoran Erlic et al.   Hormones-International Journal of Endocrinology and Metabolism

Germline Mutations of theTMEM127Gene in Patients with Paraganglioma of Head and Neck and Extraadrenal Abdominal Sites

(2011) Hartmut P. H. Neumann et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

(2011) Iñaki Comino-Méndez et al.   NATURE GENETICS

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

(2011) Vivek Subbiah et al.   PLoS One

Pheochromocytomas: The (pseudo)-hypoxia hypothesis

(2010) Judith Favier et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

(2010) Kathrin Zitzmann et al.   CANCER LETTERS

SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling

(2010) Annika Blank et al.   ENDOCRINE-RELATED CANCER

A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma

(2010) Nelly Burnichon et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

SDHA is a tumor suppressor gene causing paraganglioma

(2010) Nelly Burnichon et al.   HUMAN MOLECULAR GENETICS

Spectrum and Prevalence of FP/TMEM127 Gene Mutations in Pheochromocytomas and Paragangliomas

(2010) Li Yao et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas

(2010) Elena López-Jiménez et al.   MOLECULAR ENDOCRINOLOGY

Germline mutations in TMEM127 confer susceptibility to pheochromocytoma

(2010) Yuejuan Qin et al.   NATURE GENETICS

Regulation of Gene Expression in Hepatic Cells by the Mammalian Target of Rapamycin (mTOR)

(2010) Rosa H. Jimenez et al.   PLoS One

Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature

(2009) Lucia Martiniova et al.   CLINICAL & EXPERIMENTAL METASTASIS

Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies

(2009) L. Santarpia et al.   HORMONE AND METABOLIC RESEARCH

Treatment of Malignant Pheochromocytoma

(2009) R. Adjallé et al.   HORMONE AND METABOLIC RESEARCH

Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)

(2009) M. R. Druce et al.   HORMONE AND METABOLIC RESEARCH

Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma

(2009) K.-S. Park et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase Mutations Are Rare in Pheochromocytomas and Paragangliomas

(2009) José Gaal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis

(2009) Francien H van Nederveen et al.   LANCET ONCOLOGY

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt–mTOR–p70S6K pathway in human medullary thyroid carcinoma cells

(2009) Simona Grozinsky-Glasberg et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

New targets and therapeutic approaches for endocrine malignancies☆

(2009) Martin Fassnacht et al.   PHARMACOLOGY & THERAPEUTICS

The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas

(2009) Judith Favier et al.   PLoS One

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma

(2009) H.-X. Hao et al.   SCIENCE

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

TORC1 Is Essential for NF1-Associated Malignancies

(2008) Cory M. Johannessen et al.   CURRENT BIOLOGY

The kinesin KIF1B  acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor

(2008) S. Schlisio et al.   GENES & DEVELOPMENT

A germline mutation of the KIF1Bβ gene on 1p36 in a family with neural and nonneural tumors

(2008) I-Tien Yeh et al.   HUMAN GENETICS

Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma

(2008) Anthony M. Joshua et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors

(2008) Camilo Jimenez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate

(2008) Noah M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY

PHD2Mutation and Congenital Erythrocytosis with Paraganglioma

(2008) Charline Ladroue et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PTEN–PI3K pathway: of feedbacks and cross-talks

(2008) A Carracedo et al.   ONCOGENE

Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1

(2008) J. Zhu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

(2007) Simona Grozinsky-Glasberg et al.   NEUROENDOCRINOLOGY